近日，华海药业宣布获得国家药品监督管理局核准签发的左卡尼汀注射液《药品注册证书》。左卡尼汀（L-Carnitine）是一种天然存在于人体内的氨基酸衍生物，主要参与脂肪酸代谢，帮助将长链脂肪酸转运至线粒体进行氧化供能。临床上，左卡尼汀注射液常用于治疗因左卡尼汀缺乏引起的疾病，如慢性肾功能衰竭患者在接受血液透析过程中出现的继发性肉碱缺乏症，以及某些遗传性代谢障碍。此次获批标志着华海药业在心脑血管及代谢类药物领域进一步拓展产品管线，增强其在注射剂市场的竞争力。作为国内领先的制药企业之一，华海药业长期致力于高质量仿制药和创新药的研发与生产，已有多款产品通过一致性评价并实现出口。左卡尼汀注射液的上市不仅满足了国内患者的临床用药需求，也为公司带来新的增长点。未来，华海药业将继续推进国际化战略，加快高技术壁垒制剂的研发进度，为全球患者提供安全、有效、可负担的治疗选择。
Recently, Huahai Pharmaceutical announced that it has received the Drug Registration Certificate for L-Carnitine Injection from China’s National Medical Products Administration (NMPA). L-Carnitine is a naturally occurring amino acid derivative in the human body that plays a key role in fatty acid metabolism by facilitating the transport of long-chain fatty acids into mitochondria for energy production. Clinically, L-Carnitine Injection is commonly used to treat conditions caused by carnitine deficiency, such as secondary carnitine deficiency in patients with chronic renal failure undergoing hemodialysis, as well as certain inherited metabolic disorders.This approval marks a strategic expansion of Huahai’s product portfolio in cardiovascular and metabolic therapeutics, strengthening its position in the injectables market. As a leading Chinese pharmaceutical company, Huahai has long been committed to the research, development, and manufacturing of high-quality generic and innovative drugs, with numerous products having passed China’s consistency evaluation and achieved international exports. The launch of L-Carnitine Injection not only addresses unmet clinical needs domestically but also opens a new growth avenue for the company.Looking ahead, Huahai Pharmaceutical will continue advancing its global strategy and accelerate the development of complex, high-barrier formulations to provide safe, effective, and affordable treatment options for patients worldwide.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/9439.html